Skip to content

Insulet PODD Investments - Amortized Cost Basis

Investments - Amortized Cost Basis at other companies

Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's investments - amortized cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's investments - amortized cost basis?
Insulet (PODD) reported investments - amortized cost basis of $19.1M in Q1 2026.
How has Insulet's investments - amortized cost basis changed year-over-year?
Insulet's investments - amortized cost basis decreased by 0.0% year-over-year, from $19.1M to $19.1M.
What is the long-term trend for Insulet's investments - amortized cost basis?
Over 2 years (2023 to 2025), Insulet's investments - amortized cost basis has grown at a 40.3% compound annual growth rate (CAGR), from $9.7M to $19.1M.